What is Processa Pharmaceuticals?
Processa Pharmaceuticals is a development-stage biopharmaceutical company dedicated to enhancing the quality of life for individuals afflicted with severe chronic diseases. The company's strategic focus is on the development of pharmacological solutions, particularly within oncology and other therapeutic areas marked by substantial unmet medical needs. By concentrating on the development phase rather than initial discovery, Processa aims to create effective treatments for patients with limited therapeutic options. The company's leadership team brings extensive expertise in regulatory science and clinical development, employing a patient-centric and de-risked approach designed to expedite the market entry of novel therapies.
How much funding has Processa Pharmaceuticals raised?
Processa Pharmaceuticals has raised a total of $12.9M across 3 funding rounds:
Debt
$2.6M
Debt
$150K
Share Placement
$10.2M
Debt (2017): $2.6M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Share Placement (2021): $10.2M, investors not publicly disclosed
Key Investors in Processa Pharmaceuticals
PPP
Public-Private Partnership
What's next for Processa Pharmaceuticals?
The substantial enterprise-level funding positions Processa Pharmaceuticals for accelerated growth and the advancement of its therapeutic pipeline. With a clear strategy focused on developing existing pharmacological solutions, the company is poised to navigate the complexities of clinical trials and regulatory approvals. Future investments will likely be directed towards expanding clinical development programs, scaling manufacturing capabilities, and potentially forging strategic partnerships to broaden market reach. The company's patient-centric and de-risked development model suggests a continued emphasis on efficiency and a clear path toward bringing impactful treatments to patients with critical unmet needs.
See full Processa Pharmaceuticals company page
